The company’s board has approved to raise funds by way of issuance of equity shares, convertible preference shares or debentures or other means through one or more qualified institutions placement for an aggregate amount not exceeding Rs 350 crore, the drug firm said in a regulatory filing., The company’s board has approved to raise funds by way of issuance of equity shares, convertible preference shares or debentures or other means through one or more qualified institutions placement for an aggregate amount not exceeding Rs 350 crore, the drug firm said in a regulatory filing., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way